o-<(Methylsulfonyl)-methyl>-anisole | 25195-39-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: o-<(Methylsulfonyl)-methyl>-anisole
• 英文别名: (2-methoxybenzyl)methylsulfone；1-Methanesulfonylmethyl-2-methoxy-benZene；1-methoxy-2-(methylsulfonylmethyl)benzene
• CAS: 25195-39-5
• 化学式: C₉H₁₂O₃S
• 分子量: 200.258
• InChiKey: KXJNMUVDHMKDFH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-二苯甲基氮杂环丁烷-3-酮 、 o-<(Methylsulfonyl)-methyl>-anisole 生成 1-benzhydryl-3-[(2-methoxyphenyl)-(methylsulfonyl)methyl-(RS)]azetidin-3-ol
  参考文献：
  名称：

  Azetidine derivatives, their preparation and medicaments containing them

  摘要：

  本发明涉及通式(1)的化合物，其中：R代表链(A)或(B)；R1是甲基或乙基；R2是可任选取代的芳香环或可任选取代的杂芳香环；R3和R4，相同或不同，是可任选取代的芳香环或可任选取代的杂芳香环；R′代表氢原子或—CO—烷基，它们的光学异构体，它们的盐，它们的制备方法以及含有它们的药物。

  公开号：

  US20020035102A1
• 作为产物：
  描述：

  sodium methansulfinate 、 2-甲氧基氯化苄 生成 o-<(Methylsulfonyl)-methyl>-anisole
  参考文献：
  名称：

  Azetidine derivatives, their preparation and medicaments containing them

  摘要：

  本发明涉及通式(1)的化合物，其中：R代表链(A)或(B)；R1是甲基或乙基；R2是可任选取代的芳香环或可任选取代的杂芳香环；R3和R4，相同或不同，是可任选取代的芳香环或可任选取代的杂芳香环；R′代表氢原子或—CO—烷基，它们的光学异构体，它们的盐，它们的制备方法以及含有它们的药物。

  公开号：

  US20020035102A1

文献信息

• HALOALKYLSULFONANILIDE DERIVATIVE
  申请人：Kai Masanori

  公开号：US20120029187A1

  公开（公告）日：2012-02-02

  Novel herbicides are provided. A haloalkylsulfonanilide derivative represented by the formula (1) or an agrochemically acceptable salt thereof: the formula (1): wherein Z is —C(R 9 )(R 10 )— or —N(R 11 )—, A is an oxygen atom, a sulfur atom or —N(R 12 )—, W is an oxygen atom or a sulfur atom, m is an integer of from 0 to 3, n is an integer of from 0 to 3, m+n is from 1 to 3, R 1 is halo C 1 -C 6 alkyl, R 2 is a hydrogen atom, C 1 -C 6 alkyl or the like, each of R 3 and R 4 is independently a hydrogen atom, C 1 -C 6 alkyl or the like, each of R 5 , R 6 , R 7 , R 8 , R 9 and R 10 is independently a hydrogen atom, a halogen, C 1 -C 6 alkyl or the like, each of R 11 and R 12 is a hydrogen atom, C 1 -C 6 alkyl, halo C 1 -C 6 alkyl or the like, and X is independently a hydrogen atom, a halogen, C 1 -C 6 alkyl, or the like.

  提供新型除草剂。 一种由式（1）表示的卤烷基磺酰苯胺衍生物或其农药可接受的盐： 式（1）： 其中Z为—C(R9)(R10)—或—N(R11)—，A为氧原子、硫原子或—N(R12)—，W为氧原子或硫原子，m为0至3的整数，n为0至3的整数，m+n为1至3，R1为卤代C1-C6烷基，R2为氢原子、C1-C6烷基或类似物，R3和R4中的每一个独立地为氢原子、C1-C6烷基或类似物，R5、R6、R7、R8、R9和R10中的每一个独立地为氢原子、卤素、C1-C6烷基或类似物，R11和R12中的每一个为氢原子、C1-C6烷基、卤代C1-C6烷基或类似物，X独立地为氢原子、卤素、C1-C6烷基或类似物。
• [EN] PEPTIDIC COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS<br/>[FR] COMPOSES PEPTIDIQUES EN TANT QU'INHIBITEURS DE LA PROTEASE A CYSTEINE
  申请人：AXYS PHARM INC

  公开号：WO2004000838A1

  公开（公告）日：2003-12-31

  The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

  本发明涉及一种抑制半胱氨酸蛋白酶的化合物，特别是卡特普辛B、K、L、F和S，因此在治疗由这些蛋白酶介导的疾病方面具有用途。本发明涉及包含这些化合物的药物组合物以及制备它们的方法。
• [EN] AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS<br/>[FR] COMPOSES AMIDINO SERVANT D'INHIBITEURS DE PROTEASES A CYSTEINE
  申请人：AXYS PHARMACEUTICALS

  公开号：WO2004108661A1

  公开（公告）日：2004-12-16

  The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

  本发明涉及一种抑制半胱氨酸蛋白酶的化合物，特别是包括B、K、L、F和S半胱氨酸蛋白酶，因此在治疗由这些蛋白酶介导的疾病方面具有用处。本发明涉及包含这些化合物的药物组合物以及其制备方法。
• [EN] HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS<br/>[FR] COMPOSES CONTENANT UN HALOALKYLE UTILISE COMME INHIBITEURS DE CYSTEINE PROTEASE
  申请人：AXYS PHARM INC

  公开号：WO2005028454A1

  公开（公告）日：2005-03-31

  The application is directed to haloalkyl-substituted compounds of Formula (I), wherein R1, R1a, R2, R3, R4’ and E are as defined in the claims. The compounds are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. Pharmaceutical compositions comprising these compounds and their use are also disclosed.

  该应用程序针对式(I)的卤代烷基取代化合物，其中R1、R1a、R2、R3、R4'和E如索权中所定义。这些化合物是半胱氨酸蛋白酶的抑制剂，特别是卡托普斯蛋白酶B、K、L、F和S，因此可用于治疗由这些蛋白酶介导的疾病。还公开了包含这些化合物的药物组合物及其用途。
• CATHEPSIN INHIBITORS FOR THE TREATMENT OF BONE CANCER AND BONE CANCER PAIN
  申请人：Booth Robert

  公开号：US20120282267A1

  公开（公告）日：2012-11-08

  The present invention is directed to methods of using compounds that are inhibitors of cysteine proteases, in particular, of both cathepsins S and K and optionally further cathepsins B and/or L in treating bone cancer. The present invention is directed to pharmaceutical compositions comprising these compounds for treating bone cancer and bone cancer pain, especially the pain associated with metastasis. A single compound can be used to ameliorate the pain, the injury to bone, while also reducing tumor growth, the risk of metastasis and/or invasiveness of the cancer.

  本发明涉及使用抑制蛋白酶半胱氨酸蛋白酶的化合物的方法，特别是用于治疗骨癌的卡特普辛S和K以及可选地进一步的卡特普辛B和/或L。本发明涉及含有这些化合物的药物组合物，用于治疗骨癌和骨癌疼痛，尤其是与转移有关的疼痛。单一化合物可用于缓解疼痛、骨折伤，同时减少肿瘤生长、转移风险和/或癌症的侵袭性。